Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human APOB Antibodies:
anti-Rat (Rattus) APOB Antibodies:
anti-Mouse (Murine) APOB Antibodies:
Go to our pre-filtered search.
Human Monoclonal APOB Primary Antibody for ICC, FACS - ABIN968961
Peterson, Mack, Hall, Alsup, Alexander, Sully, Sawires, Cheung, Otto, Gresham: Apolipoprotein B Is an innate barrier against invasive Staphylococcus aureus infection. in Cell host & microbe 2008
Show all 2 Pubmed References
Guinea Pig Polyclonal APOB Primary Antibody for ID - ABIN2477467
Hazell, Arnold, Flowers, Waeg, Malle, Stocker: Presence of hypochlorite-modified proteins in human atherosclerotic lesions. in The Journal of clinical investigation 1996
Show all 4 Pubmed References
Human Polyclonal APOB Primary Antibody for RID, WB - ABIN152417
Tsai, Hsu, Hsu, Lai, Chen, Shen, Huang, Chen, Lee, Tsai, Hsu, Wu, Huang, Shiao, Hsiao, Tsou: MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. in The Journal of clinical investigation 2012
Human Polyclonal APOB Primary Antibody for ELISA, WB - ABIN449695
Benn, Nordestgaard, Jensen, Tybjaerg-Hansen: Polymorphisms in apolipoprotein B and risk of ischemic stroke. in The Journal of clinical endocrinology and metabolism 2007
Human Polyclonal APOB Primary Antibody for IHC (p), IP - ABIN267960
Bakillah, Tedla, Ayoub, John, Norin, Hussain, Brown: Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants. in Mediators of inflammation 2015
Human Monoclonal APOB Primary Antibody for RIA, ELISA - ABIN535615
Lin, Gordon, Wetterau: Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. in Journal of lipid research 1995
Show all 2 Pubmed References
Human Polyclonal APOB Primary Antibody for IF (p), IHC (p) - ABIN872950
Choi, de Poot, Lee, Kim, Han, Kim, Finley, Lee: Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation. in Nature communications 2016
Human Monoclonal APOB Primary Antibody for FACS, IF - ABIN965573
Benn: Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. in Atherosclerosis 2009
Show all 2 Pubmed References
Human Polyclonal APOB Primary Antibody for IP, ELISA - ABIN2477466
Davidson, Appel, Doster, Baker, Brown: Diseases and parasites of red foxes, gray foxes, and coyotes from commercial sources selling to fox-chasing enclosures. in Journal of wildlife diseases 1993
Show all 2 Pubmed References
APOB rs11279109 is associated with increased risk of coronary heart disease in Kuwaiti population.
The simultaneous retention of fibrinogen and APOB-lipoproteins in FSD can be detected in routinely stained histological sections. The analysis of protein structures unraveled the pathomorphogenesis of this unexpected phenomenon. Fibrinogen gamma chain (show FGG Antibodies) mutations provoke conformational changes in the region of the globular domain involved in the "end-to-end" interaction, thus impairing the D-dimer formation
APOB polymorphism rs679899 is associated with type 2 diabetes and glutamyl transpeptidase levels, while the LIPC polymorphism rs6083 may influence plasma lipid levels in Chinese Han population.
We present a case of homozygous familial defective apolipoprotein B-100 due to APOB R3500Q (rs5742904) treated with evolocumab ..Identification of a patient homozygous for familial defective apolipoprotein B-100(FDB) and successful treatment with PCSK9 (show PCSK9 Antibodies) inhibition
Increased LDL levels were observed over time in patients with the -7673G>A polymorphism of the ApoB gene.
Review/Meta-analysis: significant association of APOB rs1801701 GA, and APOB rs1042031 GA with increased risk of ischemic stroke.
Serum apoB/A-I ratio appears to have value for predicting SAP (show APCS Antibodies) in patients with AP.
Apolipoprotein B is associated with carotid atherosclerosis progression
Results show differences in the apoB100 secondary structure content among lipoproteins incubated at pH 7.4 or at pH 5.0 that could resemble those occurring in the early or late endosomes, respectively.
Elevated serum apoB levels independently predict an increased risk for incident non-alcoholic fatty liver disease.
This study demonstrates that prevention of renal apoB accumulation is a mechanism by which TGF-beta (show TGFB1 Antibodies) inhibition is nephroprotective.
Atorvastatin therapy did not show cholesterol-independent effects on inflammation in atherosclerotic lesions in Ldlr (show LDLR Antibodies)(-/-)Apob(100/100) mice, whereas a cholesterol-lowering diet intervention was effective.
A peptide fragment of apoB-100 altered the immune-dominant epitope of CD8 (show CD8A Antibodies)+ T cells and reduced atherosclerosis.
BI-1-mediated enhancement of ApoB secretion regulates hepatic lipid accumulation.
enhanced VLDL TG secretion in the absence of hepatocyte ABCA1 (show ABCA1 Antibodies) is due to altered intracellular trafficking of apolipoprotein B (apoB), resulting in augmented TG addition to nascent VLDL.
We carried out our experiment in mice deficient in the low density lipoprotein (LDL) receptor (show LDLR Antibodies) and expressing only ApoB100 molecule (ApoB - LDLr (show LDLR Antibodies)) where the development of atherosclerosis is known to closely mimic human atherosclerosis
The effect of hypercholesterolemia induced immune response and inflammation on progression of atherosclerosis in ApoB(tm25gy) LDLr (show LDLR Antibodies)(tm1Her) mice, expressing only ApoB100 and deficient in the low density lipoprotein receptor (show LDLR Antibodies).
ApoB-containing lipoproteins contribute to augmentation of AngII-induced abdominal aortic aneurysms in male mice.
Immunization with human apolipoprotein B100 (ApoB) resulted in four-fold increased accumulation of effector T cells in ApoB-containing matrigel
PCSK9 (show PCSK9 Antibodies) markedly increases intestinal triglyceride-rich apoB production through mechanisms mediated in part by transcriptional effects on apoB.
The clinicopathological phenotype of affected Holstein cattle homozygous for the causative apolipoprotein B gene (APOB) mutation associated with cholesterol deficiency is described.
Beyond malabsorption of dietary lipids, deleterious effects of apolipoprotein B deficiency on hepatic lipid metabolism, steroid biosynthesis, and cell membrane function can be expected, which may result in unspecific symptoms of reduced fertility, growth, and health.
Cholesterol deficiency results from a 1.3kbp insertion of an endogenous retrovirus (ERV2-1-LTR_BT) into exon 5 of the APOB gene at BTA11:77,959kb. The insertion is flanked by 6bp target site duplications as described for insertions mediated by retroviral integrases.
A transposable element insertion in APOB causes cholesterol deficiency in Holstein cattle
Nonesterified fatty acids significantly inhibit the expression of ApoB100, ApoE (show APOE Antibodies), MTP (show MTTP Antibodies), and LDLR (show LDLR Antibodies), thereby decreasing the synthesis and assembly of VLDL and inducing TG accumulation in bovine hepatocytes.
after calving the apolipoprotein B(100) mRNA synthesis was lower, whereas microsomal triglyceride transfer protein (MTP (show MTTP Antibodies)) and apolipoprotein E (show APOE Antibodies) messenger RNA abundance were higher in the liver.
found association between genotypes for LDLR (show LDLR Antibodies) and APOB polymorphisms and serum lipid levels, but none of them seem to be the causal mutation but probably represent closely linked polymorphisms
This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels.
, apolipoprotein B (including Ag(x) antigen)
, apolipoprotein B-100
, apolipoprotein B48
, mutant Apo B 100
, apolipoprotein B PI
, apolipoprotein B-48
, apolipoprotein B